These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34049720)

  • 1. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Zhu VW; Zhao JJ; Gao Y; Syn NL; Zhang SS; Ou SI; Bauer KA; Nagasaka M
    Lung Cancer; 2021 Jul; 157():147-155. PubMed ID: 34049720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
    Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
    ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events.
    Ng TL; Smith DE; Mushtaq R; Patil T; Dimou A; Yang S; Liu Q; Li X; Zhou C; Jones RT; Tu MM; Yan F; Bowman IA; Liu SV; Newkirk S; Bauml J; Doebele RC; Aisner DL; Gao D; Ren S; Camidge DR
    J Thorac Oncol; 2019 Apr; 14(4):596-605. PubMed ID: 30543838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
    Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Alexander M; Pavlakis N; John T; O'Connell R; Kao S; Hughes BGM; Lee A; Hayes SA; Howell VM; Clarke SJ; Millward M; Burbury K; Solomon B; Itchins M
    Lung Cancer; 2020 Apr; 142():34-40. PubMed ID: 32087434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
    Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
    J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
    Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
    Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations.
    Liu Y; Wang W; Wu F; Gao G; Xu J; Li X; Zhao C; Yang S; Mao S; Pan Y; Jia K; Shao C; Chen B; Ren S; Zhou C
    Transl Lung Cancer Res; 2021 Mar; 10(3):1512-1524. PubMed ID: 33889526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
    Muñoz-Unceta N; Zugazagoitia J; Manzano A; Jiménez-Aguilar E; Olmedo ME; Cacho JD; Oliveira J; Dómine M; Ortega-Morán L; Aguado C; Luna AM; Fernández L; Pérez J; Font C; Salvador C; Corral J; Benítez G; Ros S; Biosca M; Calvo V; Martínez J; Sánchez-Cánovas M; López R; Sereno M; Mielgo X; Aparisi F; Carmona M; Carrión R; Ponce-Aix S; Soares M; Martínez-Salas I; García-Morillo M; Juan-Vidal O; Blasco A; Muñoz AJ; Paz-Ares L;
    Eur J Cancer; 2020 Dec; 141():193-198. PubMed ID: 33166862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
    Song Z; Su H; Zhang Y
    Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent thrombosis followed by Lazarus response in
    Beninato T; Lo Russo G; Garassino MC; De Braud F; Platania M
    Tumori; 2020 Dec; 106(6):NP41-NP45. PubMed ID: 32066344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.